Recipe for a new imaging biomarker: carefully combine target, reagent, and technology  by Kobayashi, Hisataka & Choyke, Peter L.
commentar y
Kidney International (2012) 81     129
dysfunction, nor did the FVB / N pure-
background mice, whereas the  Ctns   −  /  −  
mice on a pure C57BL / 6 background 
developed renal dysfunction as early as 6 
months of age and end-stage renal failure 
by 15 months. 11 Th e identifi cation of these 
other genes that infl uence the severity of 
the disease in the context of cystinosis 
should be of high interest and would help 
to better understand the physiopathology 
of cystinosis and the high variability of 
symptoms even with cysteamine therapy. 
 What is the outlook for patients with 
cystinosis? A new, delayed-release formu-
lation of cysteamine (DR Cysteamine) is 
currently being developed by Raptor 
Pharmaceutical on the basis of a study 
conducted by Dohil  et al. 12 Th e company 
recently completed its pivotal, phase 3 
clinical study. Th is new formulation needs 
to be taken twice daily, so the patients will 
be able to sleep through the night, and it 
will reduce the gastrointestinal side eff ects. 
Th us, the patients ’ quality of life will be 
improved, but will the impact on the dis-
ease also be improved? Hematopoietic 
stem cell transplantation, which has a sig-
nifi cant therapeutic benefi t in the mouse 
model of cystinosis, 13,14 could be the next 
treatment for cystinosis. However, proof 
that cell therapy has the same benefi ts in 
patients as in mice still needs to be dem-
onstrated. 
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 Recipe for a new imaging 
biomarker: carefully combine 
target, reagent, and technology 
 Hisataka  Kobayashi 1 and  Peter L.  Choyke 1 
 A careful combination of biological targeting moieties (C3 fragments), 
imaging reagents (a small particle of iron oxide), and appropriate 
technology (T2-weighted magnetic resonance imaging) is the key to the 
successful development of an imaging agent for glomerulonephritis. 
This recipe applies to virtually any molecular imaging probe for the 
kidney and throughout the body. However, each organ and disease 
requires a unique combination of these three components in order to 
achieve success. 
 Kidney International (2012)  81, 129 – 131.  doi: 10.1038/ki.2011.374 
 1 Molecular Imaging Program, Center for Cancer 
Research, National Cancer Institute, National 
Institutes of Health ,  Bethesda ,  Maryland ,  USA 
 Correspondence: Hisataka Kobayashi, 
Molecular Imaging Program, National Cancer 
Institute / NIH, Building 10, Room B3B69, MSC 1088, 
Bethesda, Maryland 20892-1088, USA. 
E-mail:  Kobayash@mail.nih.gov 
 Kidney biopsy is the traditional method 
of diagnosing glomerulonephritis. How-
ever, there is a growing understanding 
that noninvasive imaging biomarkers 
could replace, or at least reduce the need 
for, biopsy. Imaging has the advantage that 
it is noninvasive and, therefore, could 
be repeatedly used to evaluate disease 
status. Rapid progress has been made in 
molecular imaging, which makes possible 
targeted probes that could only be hypo-
thesized a decade ago. Nevertheless, in 
reality, there are few examples of success-
ful molecular probes for specifi c diseases. 
Even fewer have been reported with mag-
netic resonance imaging (MRI), despite its 
inherent advantage of not using ionizing 
radiation. Unfortunately, MRI suffers 
from lower sensitivity compared with 
radionuclide methods. Sargsyan  et al. 1 
(this issue) report the development of just 
such a new MRI biomarker and demon-
strate its utility in a lupus nephritis model. 
It uses a targeting agent for C3 activation 
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fragments conjugated to an iron oxide 
particle that binds C3 fragments in suffi  -
cient quantities to be detected by MRI. By 
carefully selecting the biological target 
(C3 activation fragments), combining it 
with an imaging agent (small iron oxide 
nanoparticles), and using appropriate 
imaging technology (T2-weighted MRI), 
the authors demonstrate the feasibility of 
developing a potentially useful imaging 
biomarker for clinical application. Th eir 
experience holds important lessons for 
those seeking to develop novel imaging 
biomarkers. 
 Th e challenges facing the development 
of such an agent are formidable. Glome-
rulonephritis is easily masked by the 
excretion of imaging contrast agents, 
which is oft en by way of the kidney. A fun-
damental principle of imaging is that in 
order to localize abnormal signal, it is fi rst 
necessary to visualize the background 
anatomy in high spatial resolution but 
with relatively homogeneous low back-
ground signal, so that any abnormality 
stands out like a star against a black sky. 
From this point of view, MRI is an appro-
priate choice because it displays the nor-
mal kidney at high resolution with 
relatively homogeneous signal on both 
T1- and T2-weighted sequences. 2,3 Th e 
next challenge is to deliver the agent to the 
kidney such that nonspecifi c accumula-
tion can be diff erentiated from binding to 
the target molecule. Th e targets in this 
case are deposits of C3 activation frag-
ments, located in and around the glomer-
ulus. High blood fl ow to the glomerulus 
ensures that delivery of the agent will be 
rapid and effi  cient. However, in order to 
obtain specifi c signal from the target, the 
unbound imaging agent must be rapidly 
cleared from the kidney. Since the major 
function of the glomeruli is fi ltration of 
small molecules, the kidneys are often 
the main route of excretion of imaging 
agents, even when they are several nano-
meters in diameter. 4,5 Renal excretion 
causes increased background signal and 
will mask the signal from the bound imag-
ing agent. Even if the agent is not cleared 
rapidly and remains in the blood pool 
with long circulation times, it can produce 
background signal that will interfere 
with target-specific signal. Over time, 
such blood pool agents will leak from the 
vessels and cause nonspecifi c background 
signal in the interstitial fl uid, where they 
are engulfed by macrophages and den-
dritic cells. For this application, most 
gadolinium-based contrast agents are 
too small and will rapidly be excreted. 
Ultra small nanoparticles of iron oxide 
(USPIOs), which are considerably larger 
than gadolinium chelates (20 – 30  nm in 
diameter), have been used to demonstrate 
infl ammatory foci in the kidney induced 
by ischemia and reperfusion injury based 
on activated phagocytosis of USPIOs by 
tissue macrophages. 2 Even larger mole-
cules such as small particles of iron oxide 
(SPIOs, about 200  nm in diameter) have 
the added advantage of clearance through 
the liver instead of the kidney but still can 
leak into areas of glomerulonephritis, 
where they can bind C3 activation frag-
ments with relatively low background 
signal. Thus, by carefully combining 
targeting molecules for C3 activation frag-
ments (biological target) with an SPIO 
platform (chemical agent), and detecting 
pathological signal on T2-weighted MRI 
(imaging technology), a successful imag-
ing biomarker was designed ( Figure 1 ). It 
is important to understand that this design 
is well suited for targets located in and 
around the glomerulus but might not 
work as well for targets away from the 
glomerulus, including in the proximal and 
distal tubules. For such targets, nanomate-
rial-based imaging agents must be fl exibly 
designed to fi t a specifi c target. 
 Th ere are important lessons here for 
the design of imaging agents for other 
organs. Diff erent sites of the body have 
distinct physiology, blood supply, and tis-
sue composition; therefore, each imaging 
agent must be uniquely designed based 
on the proper target, reagent, and imaging 
modality. 6 However, thinking beyond the 
current  ‘ one probe, one disease ’ paradigm, 
there are expanding efforts to develop 
multiplexed 7 and activatable signaling. 8 
Multiplexed imaging refers to techniques 
that yield multiple distinct data sets from 
a single imaging session. Th ree general 
strategies for multiplexed imaging have 
been proposed: (1) multiple modality, in 
which two (or more) distinct imaging 
modalities are simultaneously or consecu-
tively used; (2) multiple color imaging 
agents, in which multiple diff erent agents, 
with distinct energies (colors), are simul-
taneously imaged by a single modality; 
and (3) multiple signal collection, in 
which a single modality can detect and 
interpret multiple signals obtained with 
distinct signaling technologies. Activata-
ble signaling uses  ‘ smart ’ reagents that 
emit signal in target tissue only after 
cellular internalization or other triggering 
events. 9,10 Multiplexed and activatable 
strategies overcome the limitations of a 
single modality or a single target. For 
instance, there is usually a trade-off 
between anatomic resolution and sensitiv-
ity such that combining a high-sensitivity 
technique (such as positron emission 
tomography scanning) with a high-reso-
lution technique (such as computed tom-
ography scanning) makes sense. Similarly, 
one target provides a limited amount of 
information, whereas a profi le of targets 
provides more enriched information. 
However, even with multiplexing, the 
basics remain the same: the target, rea-
gent, and imaging modality must be care-
fully chosen to maximize the utility of the 
probe. Even for multiplexing, each one of 
the imaging agents and modalities should 
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 Figure 1  |  Schematic showing the strategy for developing a target-specific molecular 
imaging agent, which can be used as a biomarker of a disease. 
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be designed carefully and work appropri-
ately. Th us, the imaging agent designed 
by Sargsyan  et al. 1 is quite promising 
and forms the basis to develop successful 
multiplexed imaging agents, which will 
noninvasively obtain more complete 
information about disease status than is 
now possible. 
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